THE EFFECT AND INTERACTION ASPIRIN AND TICLOPIDINE ON HEMATOLOGICAL VARIABLES IN RATS

Z. Stanojević ,
Z. Stanojević

Institute of Pharmacology and Toxicology, Medical Faculty Pristina , Kosovska Mitrovica , Kosovo*

R. Mitić ,
R. Mitić

Institute of Pharmacology and Toxicology, Medical Faculty Pristina , Kosovska Mitrovica , Kosovo*

V. Nestorović ,
V. Nestorović

Institute of Physiology, Medical Faculty Pristina , Kosovska Mitrovica , Kosovo*

D. Valjarević ,
D. Valjarević

Department of mathematics, Faculty of Natural Sciences and mathematics Pristina , Kosovska Mitrovica , Kosovo*

S. Hadžistević
S. Hadžistević

Institute of Pharmacology and Toxicology, Medical Faculty Pristina , Kosovska Mitrovica , Kosovo*

Published: 01.12.2010.

Volume 38, Issue 2 (2010)

pp. 9-13;

https://doi.org/10.70949/pramed201002351S

Abstract

The combination of aspirin and ticlopidine has been proven to reduce the frequency of haemorrhagic and vascular complications after coronary artery stenting, but also can cause serious hematological side effects. The purpose of this study was to evaluate the effect and interactions aspirin and ticlopidine on hematological variables. Thirty two Wistar rats were divided in four groups and they received intraperitoneal one of the following treatments for 4 days: group I - control, group II aspirin (50 mg/kg BM), group III - ticlopidine (125 mg/kg/day) and group IV - aspirin+ticlopidine combination (50 mg/kg/day+125 mg/kg/day). Hematological variables were determined at once after taking the sample of blood. Relationship between measured variables was determined by calculating linear correlation coefficient (r). The hematocrit, haemoglobin and red blood cell were significantly decreased in group treated with aspirin+ticlopidine combination compared to control (p< 0,05). Neutrophil and platelet count weren't significantly different in treated groups, but were slightly decreased in groups treated with ticlopidine and aspirin+ticlopidine combination. Between hematocrit and platelet count in control group of rats was noticed negative and medium correlation (r=-0,41), in groups treated with ticlopidine and aspirin+ticlopidine combination positive and medium correlation (r=0,52; r=0,69). Based on obtained results it can be observed significant decreased hematocrit, haemoglobin and red blood cell in group treated with aspirin+ticlopidine combination. The negative correlation between hematocrit and platelet count in control group becomes positive after the treatment with ticlopidine alone and aspirin+ticlopidine combination.

Keywords

References

1.
B. B, terapiji N. Pregled literature o lekovima za 2000 godinu. In: VMA Institut za naučne informacije Informativni bilten 2001.
2.
A. S, F.J N. Kastrati A.: A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1084–9.
3.
H.J. R, H. D, U. B, Th. V, B. N, S G. Meyer J.: Comparison of antiplatelet effects of aspirin, ticlopidine, or their combination after stent implantation. Circulation. 97:1046–52.
4.
Berger PB, Bell MR, Rihal CS, Ting H, Barsness G, Garratt K, et al. Clopidogrel versus ticlopidine after intracoronary stent placement. J Am Coll Cardiol. 34(7):1891–4.
5.
Ch. M, H. R, F.J. N, P. H, S. M, A P. Buettner H.J.: A randomised comparison of clopidogrel and aspirin versus ticlopidine and aspirin after the placement of coronary artery stents. J Am Coll Cardiol. 41(6):969–73.
6.
Stanojević Z. Efekt i interakcija aspirina i tiklopidina na hematološke i biohemijske varijable u eksperimentalnih pacova. Magistarski rad, Kosovska Mitrovica.
7.
K. O, K. K, M Y. Agranulocytosis caused by ticlopidine and its mechanism. Am J Hematol. 37:239–42.
8.
F.J. N, D H. Schoming A.: Neutropenia with ticlopidine plus aspirin. Lancet. 349:1552–3.
9.
A. S, F.J N. Kastrati A.: A randomised comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 334:1084–9.
10.
A. H, W.M H. Pranhar H.: Neutropenia with ticlopidine plus aspirin. Lancet. 349:474–5.
11.
S. T, N K. Yoshida T.: Ticlopidine and thrombocytopenia (letter. N Engl J Med. 323:1487–8.
12.
A. L, R. E, J G. A placebo controlled trial of floctafenine (Idarac) against enteric coated acetylsalicylic acid in osteoarthritic patients. Rheumatol Rehabil. 19:52–9.
13.
E. N, A. G, M.K. P, T MK. Lamminsivu U.: Effect of acetylsalicylic acid on plasma thromboxane B2 and platelet aggregation in man. Eur J Clin Pharmacol. 25:313–7.
14.
G. P, M. P, P. T, V. B, S C. Longterm effects of ticlopidine on fibrinogen and haemorheology in patients with peripheral arterial disease. Thromb Res. 52(6):621–9.
15.
M. S, H. W, J.P C. Labie D.: In vitro study of ticlopidine, as a model of antisickling action of platelet antiaggregant. Haematologia (Budap. 17(2):199–207.

Citation

Copyright

Article metrics

Google scholar: See link

The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Most read articles

Indexed by